Stellungnahme des Rare Disease Action Forum (RDAF): „Patientenzugang bei seltenen Krankheiten sichern“

Implementation of New Outpatient Medical Tariff System from 1 January 2026 – Implications for Patients with Rare Diseases

RDAF statement on the KVV / KLV revision

Joint statement on the KVV/OAMal and KLV/OPAS revision

RDAF newsletter – June 2022

RDAF statement on the Federal Council report on rare diseases

RDAF statement for the public consultation on the adjustment of various ordinances which are needed to implement the revised Swiss Invalidity Insurance

RDAF-Workshopbericht – «Patientenbeteiligung an Entscheidungsprozessen

Swiss Rare Disease Summit 2024

Multi-stakeholder workshop report – Post-marketing registries for rare diseases

The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

Multi-stakeholder workshop report – Market access for orphan drugs in Switzerland

Report of the RDAF Multi-Stakeholder Workshop on Registries for Rare Diseases

RDAF statement for the public consultation on he revision of the Federal Health Insurance Act concerning package 2 of the cost containment measures